FrancophonIA/ELRC3.0 huggingface dataset:
English: PARAMOUNT:Kaplan Meier plot of progression-free survival (PFS) and Overall Survival (OS) for continuation pemetrexed maintenance versus placebo in patients with NSCLC other than predominantly squamous cell histology (measured from randomisation)
Croatian: PARAMOUNT: Kaplan Meierova krivulja preživljenja bez progresije bolesti (PFS) i ukupnog preživljenja (OS) za nastavak terapije održavanja pemetreksedom u odnosu na placebo u bolesnika s NSCLC-om kod kojeg histološki ne prevladavaju skvamozne stanice (mjereno od randomizacije)
English: JMEN: Kaplan Meier plots of progression-free survival (PFS) and overall survival pemetrexed versus placebo in patients with NSCLC other than predominantly squamous cell histology:
Croatian: JMEN: Kaplan Meierova krivulja preživljenja bez progresije bolesti (PFS) i ukupnog preživljenja uz primjenu pemetrekseda u odnosu na placebo u bolesnika s NSCLC-om kod kojeg histološki ne prevladavaju skvamozne stanice:
English: In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of Pemetrexed Accord is 500 mg/m2 BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Croatian: U bolesnika koji se liječe zbog raka pluća nemalih stanica nakon prethodne kemoterapije preporučena doza lijeka Pemetrexed Accord iznosi 500 mg/m2 tjelesne površine, a primjenjuje se u obliku intravenske infuzije tijekom 10 minuta, prvog dana svakog 21-dnevnog ciklusa.
English: Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2)
Croatian: Lijek se izdaje na ograničeni recept (vidjeti Prilog I: Sažetak opisa svojstava lijeka, dio 4.2).
English: A hospital pharmacist, nurse or doctor will have mixed the Pemetrexed Accord powder with 9 mg/ml (0.9 %) sodium chloride solution for injection before it is given to you.
Croatian: Prije primjene lijeka Pemetrexed Accord bolnički ljekarnik, medicinska sestra ili liječnik će pomiješati Pemetrexed Accord prašak s otopinom natrijevog klorida za injekciju od 9 mg/ml (0,9%).
English: In addition, infection with or without fever, diarrhoea, and/or mucositis may be seen.
Croatian: sa ili bez vrućice, te proljev i/ili mukozitis.
English: OTHER SPECIAL WARNING(S), IF NECESSARY CYTOTOXIC.
Croatian: DRUGO(A) POSEBNO(A) UPOZORENJE(A), AKO JE POTREBNO CITOTOKSIČNO.
English: 10.3 N = 10.3 N = 0.94a
Croatian: 0,94a
English: A multicentre, randomised, open-label, Phase 3 study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC) showed that pemetrexed plus cisplatin (Intent-To-Treat [ITT] population n= 862) met its primary endpoint and showed similar clinical efficacy as gemcitabine plus cisplatin (ITT n= 863) in overall survival (adjusted hazard ratio 0.94; 95% CI= 0.84-1.05).
Croatian: Multicentrično, randomizirano, otvoreno ispitivanje faze III pemetrekseda i cisplatina u odnosu na gemcitabin i cisplatin u bolesnika s lokalno uznapredovalim ili metastatskim (stadij IIIB ili IV) rakom pluća nemalih stanica (NSCLC) koji prethodno nisu primali kemoterapiju pokazalo je da su pemetreksed i cisplatin (ITT populacija, n = 862) ostvarili primarni ishod ispitivanja i pokazali sličnu kliničku djelotvornost kao gemcitabin i cisplatin (ITT n = 863) s obzirom na ukupno preživljenje (prilagođeni omjer rizika 0,94; 95% CI = 0,84-1,05).
English: (N = 1725) Adenocarcinoma (N=847)
Croatian: Adenokarcinom (N=847)
English: The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in > 5 % of 800 patients randomly assigned to receive single agent pemetrexed and 402 patients randomly assigned to receive placebo in the single-agent pemetrexed maintenance (JMEN: N= 663) and continuation pemetrexed maintenance (PARAMOUNT: N=539) studies.
Croatian: Tablica koja slijedi prikazuje učestalost i težinu nuspojava za koje se smatra da bi mogle biti povezane s ispitivanim lijekom, a koje su zabilježene u > 5% od 800 bolesnika randomiziranih da primaju samo pemetreksed i 402 bolesnika randomizirana da primaju placebo u ispitivanju monoterapije pemetreksedom kao terapije održavanja (JMEN: N= 663) i ispitivanja kontinuirane terapije održavanja pemetreksedom (PARAMOUNT: N=539).
English: Pemetrexed is incompatible with diluents containing calcium, including lactated Ringer's Injection and Ringer's Injection.
Croatian: Pemetreksed je inkompatibilan s otapalima koja sadrže kalcij, uključivši Ringerovu otopinu s laktatom i Ringerovu otopinu za injekcije.
English: In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Accord and cisplatin is documented in Table 3.
Croatian: Preporučena prilagodba doze lijeka Pemetrexed Accord i cisplatina u slučaju neurotoksičnosti navedena je u Tablici
English: Pemetrexed Accord contains sodium
Croatian: Pemetrexed Accord sadrži natrij
English: An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of pemetrexed versus docetaxel for other than predominantly squamous histologies (n= 399, 9.3 versus 8.0 months, adjusted HR= 0.78; 95% CI= 0 .61-1.00, p= 0.047) and was in favour of docetaxel for squamous cell carcinoma histology (n= 172, 6.2 versus 7.4 months, adjusted HR= 1.56;95% CI = 1.08-2.26, p = 0.018).
Croatian: Analiza utjecaja histologije NSCLC-a na učinak liječenja na ukupno preživljenje pokazuje prednost pemetrekseda u odnosu na docetaksel u tumora kod kojih histološki ne prevladavaju skvamozne stanice (N=399, 9,3 naspram 8,0 mjeseci, prilagođeni omjer hazarda (engl. hazard ratio) HR = 0,78; 95% CI = 0,61-1,00, p = 0,047) i prednost docetaksela u slučaju tumora kod kojih histološki prevladavaju skvamozne stanice (N=172, 6,2 naspram 7,4 mjeseci, prilagođeni HR = 1,56; 95% CI = 1,08-2,26, p = 0,018).
English: Following pemetrexed plus cisplatin induction (4 cycles), treatment with pemetrexed was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio = 0.78, 95 %CI=0.64-0.96, p=0.0195).
Croatian: Nakon uvodnog liječenja pemetreksedom i cisplatinom (4 ciklusa), liječenje pemetreksedom bilo je statistički značajno bolje od placeba s obzirom na OS (medijan 13,9 mjeseci naspram 11,0 mjeseci, omjer hazarda = 0,78, 95% CI = 0,64-0,96, p = 0,0195).
English: Pemetrexed Accord 100 mg powder for concentrate for solution for infusion Pemetrexed Accord 500 mg powder for concentrate for solution for infusion Pemetrexed Accord 1000 mg powder for concentrate for solution for infusion pemetrexed
Croatian: Pemetrexed Accord 100 mg prašak za koncentrat za otopinu za infuziju Pemetrexed Accord 500 mg prašak za koncentrat za otopinu za infuziju Pemetrexed Accord 1000 mg prašak za koncentrat za otopinu za infuziju pemetreksed
English: Upon recovery patients should be retreated using the guidelines in Tables 1, 2 and 3, which are applicable for Pemetrexed Accord used as a single agent or in combination with cisplatin.
Croatian: Nakon oporavka bolesnika treba ponovno liječiti prema smjernicama za primjenu lijeka Pemetrexed Accord u monoterapiji ili u kombinaciji s cisplatinom, prikazanima u Tablicama 1, 2 i 3.
English: A multicentre, randomised, double-blind, placebo-controlled Phase 3 study (JMEN), compared the efficacy and safety of maintenance treatment with pemetrexed plus best supportive care (BSC) (n = 441) with that of placebo plus BSC (n = 222) in patients with locally advanced (Stage IIIB) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC) who did not progress after 4 cycles of first line doublet therapy containing cisplatin or carboplatin in combination with gemcitabine, paclitaxel, or docetaxel.
Croatian: U multicentričnom, randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju faze III (JMEN) uspoređivala se djelotvornost i sigurnost pemetreksedom kao terapijom održavanja uz najbolju potpornu njegu (eng. best supportive care, BSC) (n = 441) s djelotvornošću i sigurnošću primjene placeba uz BSC (n = 222) u bolesnika s lokalno uznapredovalim (stadij IIIB) ili metastatskim (stadij IV) rakom pluća nemalih stanica (NSCLC) u kojih nije došlo do progresije nakon 4 ciklusa prve linije dvojne terapije cisplatinom ili karboplatinom u kombinaciji s gemcitabinom, paklitakselom ili docetakselom.
English: Pemetrexed Accord 100 mg contains less than 1 mmol sodium (23 mg) sodium per vial, i.e. essentially ‘sodium-free'.
Croatian: Pemetrexed Accord 100 mg sadrži manje od 1 mmol natrija (23 mg) po bočici tj. zanemarive količine natrija.
English: Common SGPT (ALT) elevation SGOT (AST) elevation
Croatian: Poremećaji jetre i žuči često povišene vrijednosti ALT-a (SGPT-a) povišene vrijednosti AST-a (SGOT-a)
English: Common Neuropathy-Sensory Taste disturbance
Croatian: Poremećaji živčanog sustava često senzorna neuropatija poremećaj okusa
English: LIST OF EXCIPIENTS Mannitol, hydrochloric acid, sodium hydroxide (see package leaflet for further information).
Croatian: POPIS POMOĆNIH TVARI Manitol, kloridna kiselina, natrijev hidroksid (za dodatne informacije vidjeti Uputu o lijeku).
English: Pemetrexed Accord is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section
Croatian: Pemetrexed Accord je indicirana kao monoterapija u terapiji održavanja lokalno uznapredovalog ili metastatskog raka pluća nemalih stanica kod kojeg histološki ne prevladavaju skvamozne stanice u bolesnika u kojih bolest nije napredovala neposredno nakon kemoterapije na bazi platine (vidjeti dio 5.1).
English: The table below provides the frequency and severity of undesirable effects that have been reported in > 5 % of 265 patients randomly assigned to receive single agent pemetrexed with folic acid and vitamin B12 supplementation and 276 patients randomly assigned to receive single agent docetaxel.
Croatian: U tablici koja slijedi navedena je učestalost i težina nuspojava koje su prijavljene u > 5% od 265 bolesnika randomiziranih u skupinu koja je primala samo pemetreksed te nadomjestak folatne kiseline i vitamina B12 i 276 bolesnika randomiziranih u skupinu koja je primala samo docetaksel.
English: Irritation of the skin and itching Chest pain
Croatian: Iritacija kože i svrbež
English: Women must use effective contraception during treatment with Pemetrexed Accord.
Croatian: Žene moraju primjenjivati djelotvornu kontracepciju tijekom liječenja lijekom Pemetrexed Accord.
English: The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in > 5 % of 839 patients with NSCLC who were randomized to receive cisplatin and pemetrexed and 830 patients with NSCLC who were randomized to receive cisplatin and gemcitabine.
Croatian: Tablica koja slijedi prikazuje učestalost i težinu nuspojava za koje se smatra da bi mogle biti povezane s ispitivanim lijekom, a koje su prijavljene u > 5% od 839 bolesnika s rakom pluća nemalih stanica randomiziranih da primaju cisplatin i pemetreksed i 830 bolesnika s rakom pluća nemalih stanica randomiziranih da primaju cisplatin i gemcitabin.
English: Men are advised not to father a child during and up to 6 months following treatment with Pemetrexed Accord and should therefore use effective contraception during treatment with Pemetrexed Accord and for up to 6 months afterwards.
Croatian: Muškarcima se savjetuje da ne začinju djecu tijekom liječenja i do 6 mjeseci nakon završetka liječenja lijekom Pemetrexed Accord.
English: Clinically relevant CTC toxicity that was reported in < 1 % of the patients that were randomly assigned to pemetrexed include: allergic reaction/hypersensitivity, erythema multiforme, supraventricular arrhythmia and pulmonary embolism.
Croatian: Klinički značajni oblici toksičnost prema CTC kriterijima prijavljeni u < 1% bolesnika randomiziranih da primaju pemetreksed uključuju: alergijske reakcije/reakcije preosjetljivosti, multiformni eritem, supraventrikularnu aritmiju i plućnu emboliju.
English: The table below provides the frequency and severity of undesirable effects that have been reported in > 5 % of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed and 163 patients with mesothelioma randomised to receive single agent cisplatin.
Croatian: U tablici koja slijedi navedene su učestalost i težina nuspojava koje su prijavljene u > 5% od 168 bolesnika s mezoteliomom randomiziranih u skupinu koja je primala cisplatin i pemetreksed i 163 bolesnika s mezoteliomom randomiziranih u skupinu koja je primala samo cisplatin.
English: A statistically significant improvement of the clinically relevant symptoms (pain and dyspnoea) associated with malignant pleural mesothelioma in the pemetrexed/cisplatin arm (212 patients) versus the cisplatin arm alone (218 patients) was demonstrated using the Lung Cancer Symptom Scale.
Croatian: Lung Cancer Symptom Scale) u skupini bolesnika liječenih kombinacijom pemetreksed/cisplatin (212 bolesnika) uočeno je statistički značajno poboljšanje klinički značajnih simptoma (bol i dispneja) povezanih s malignim pleuralnim mezoteliomom u odnosu na bolesnike liječene samo cisplatinom (218 bolesnika).
English: The recommended dose of Pemetrexed Accord is 500 mg/m2 of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Croatian: Preporučena doza lijeka Pemetrexed Accord je 500 mg/m2 tjelesne površine, a primjenjuje se u obliku intravenske infuzije tijekom 10 minuta, prvog dana svakog 21-dnevnog ciklusa.
English: The median OS for the overall population (n = 663) was 13.4 months for the pemetrexed arm and 10.6 months for the placebo arm, hazard ratio = 0.79 (95% CI= 0.65-0.95, p = 0.01192).
Croatian: Medijan ukupnog preživljenja za ukupnu populaciju (n = 663) iznosio je 13,4 mjeseci u skupini koja je primala pemetreksed i 10,6 mjeseci u skupini koja je primala placebo, omjer hazarda = 0,79 (95% CI = 0,65-0,95, p = 0,01192).
English: EMPHACIS, a multicentre, randomised, single-blind phase 3 study of pemetrexed plus cisplatin versus cisplatin in chemonaive patients with malignant pleural mesothelioma, has shown that patients treated with pemetrexed and cisplatin had a clinically meaningful 2.8-month median survival advantage over patients receiving cisplatin alone.
Croatian: EMPHACIS, multicentrično, randomizirano, jednostruko slijepo ispitivanje faze III pemetrexeda i cisplatina u odnosu na monoterapiju cisplatinom u bolesnika s malignim pleuralnim mezoteliomom koji nisu ranije primali kemoterapiju, pokazalo je da je u bolesnika liječenih pemetrexedom i cisplatinom medijan preživljenja bio 2,8 mjeseci dulji nego u bolesnika liječenih samo cisplatinom, što se smatra klinički značajnom razlikom.
English: Pemetrexed Accord 500 mg contains approximately 54 mg sodium per vial.
Croatian: Pemetrexed Accord 500 mg sadrži približno 54 mg natrija po bočici.
English: Efficacy of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma Randomized and treated
Croatian: Djelotvornost pemetrekseda + cisplatina u odnosu na monoterapiju cisplatinom u bolesnika s malignim pleuralnim mezoteliomom Randomizirani i liječeni
English: There were no clinically relevant differences observed for the safety profile of pemetrexed plus cisplatin within the histology subgroups.
Croatian: Nisu uočene klinički značajne razlike u sigurnosnom profilu lijeka pemetrekseda u kombinaciji s cisplatinom unutar podskupina prema histološkom tipu.
English: Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size.
Croatian: Kratice: CI = interval pouzdanosti; ITT = populacija svih uključenih bolesnika; n = ukupan broj bolesnika.
English: Each vial contains approximately 11 mg sodium.
Croatian: Jedna bočica sadrži približno 11 mg natrija.
English: Premedication regimen
Croatian: Protokol za premedikaciju
English: Mannitol, hydrochloric acid, sodium hydroxide (see package leaflet for further information).
Croatian: POPIS POMOĆNIH TVARI Manitol, kloridna kiselina, natrijev hidroksid (za dodatne informacije vidjeti uputu o lijeku).
English: Pemetrexed Accord 1000 mg contains approximately 108 mg sodium per vial.
Croatian: Pemetrexed Accord 100 mg sadrži približno 108 mg natrija po bočici.
English: Pemetrexed Accord is a powder for concentrate for solution for infusion in a glass vial.
Croatian: Kako Pemetrexed Accord izgleda i sadržaj pakiranja Pemetrexed Accord je prašak za koncentrat za otopinu za infuziju u staklenoj bočici.
English: Each vial contains approximately 108 mg sodium.
Croatian: Jedna bočica sadrži približno 108 mg natrija.
English: GENERAL CLASSIFICATION FOR SUPPLY INSTRUCTIONS ON USE INFORMATION IN BRAILLE Justification for not including Braille accepted.
Croatian: 14. NAČIN IZDAVANJA LIJEKA 15. UPUTE ZA UPORABU 16. PODACI NA BRAILLEOVOM PISMU Prihvaćeno obrazloženje za nenavođenje Brailleovog pisma.
English: How to store Pemetrexed Accord
Croatian: Kako čuvati lijek Pemetrexed Accord
English: Pemetrexed Accord in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).
Croatian: Pemetrexed Accord je u kombinaciji s cisplatinom indicirana u prvoj liniji liječenja bolesnika s lokalno uznapredovalim ili metastatskim rakom pluća nemalih stanica kod kojeg histološki ne prevladavaju skvamozne stanice (vidjeti dio 5.1).
English: Further dilution by a healthcare provider is required prior to administration.
Croatian: Zdravstveni djelatnik mora dodatno razrijediti otopinu prije primjene.
English: The study met its primary endpoint and showed a statistically significant improvement in PFS in the pemetrexed arm over the placebo arm (n = 472, independently reviewed population; median of 3.9 months and 2.6 months, respectively) (hazard ratio = 0.64, 95 % CI = 0.51-0.81, p = 0.0002).
Croatian: Ispitivanje je ispunilo primarni ishod i pokazalo statistički značajno poboljšanje PFS-a u skupini koja je primala pemetreksed u odnosu na skupinu koja je primala placebo (n = 472, neovisno procijenjena populacija; medijan od 3,9 odnosno 2,6 mjeseci) (omjer hazarda = 0,64, 95% CI = 0,51-0,81, p = 0,0002).
English: ***According to National Cancer Institute CTC (v2.0; NCI 1998), taste disturbance and alopecia should only be reported as Grade 1 or 2.
Croatian: *** Prema CTC NCI (v2.0; NCI 1998), poremećaj osjeta okusa i alopecija prijavljuju se isključivo kao nuspojave stupnja 1 ili 2.
English: Pemetrexed Accord in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
Croatian: Pemetrexed Accord je u kombinaciji s cisplatinom indicirana za liječenje bolesnika s neoperabilnim malignim pleuralnim mezoteliomom koji prethodno nisu primali kemoterapiju.
English: Liver: abnormal blood tests
Croatian: Bubrezi: poremećeni rezultati krvnih pretraga
English: Pemetrexed Accord 1000 mg powder for concentrate for solution for infusion Type I glass vial with a grey bromobutyl rubber stopper with royal blue flip-off seal containing 1000 mg of pemetrexed.
Croatian: Pemetrexed Accord 1000 mg prašak za koncentrat za otopinu za infuziju Staklena bočica (tip I) sa sivim čepom od bromobutilne gume s kraljevski plavim „flip-off“ zatvaračem, koja sadrži 1000 mg pemetrekseda.
English: *** Integrated adverse reactions table combines the results of the JMEN pemetrexed maintenance (N=663) and PARAMOUNT continuation pemetrexed maintenance (N=539) studies.
Croatian: (N=663) i kontinuirane terapije održavanja pemetreksedom (PARAMOUNT) (N=539).
English: Clinically relevant CTC toxicity of any grade that was reported in ≥ 1 % and  5 % of the patients that were randomly assigned to pemetrexed include: febrile neutropenia, infection, decreased platelets, diarrhoea, constipation, alopecia, pruritis/itching, fever (in the absence of neutropenia), ocular surface disease (including conjunctivitis), increased lacrimation, dizziness and motor neuropathy.
Croatian: Među klinički značajne oblike toksičnosti prema CTC kriterijima, prijavljene u ≥ 1% i  5% bolesnika randomiziranih da primaju pemetreksed ubrajaju se: neutropenijska vrućica, infekcija, snižen broj trombocita, proljev, konstipacija, alopecija, pruritus/svrbež, vrućica (bez neutropenije), površinske bolesti oka (uključujući konjunktivitis), pojačano suzenje, omaglica i motorička neuropatija.
English: 50 % of previous dose a National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) Treatment with Pemetrexed Accord should be discontinued if a patient experiences any haematologic or non-haematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.
Croatian: Liječenje lijekom Pemetrexed Accord se mora obustaviti ako se u bolesnika pojavi bilo kakva hematološka ili nehematološka toksičnost stupnja 3 ili 4 nakon dvaju sniženja doze, odnosno odmah ako se ustanovi neurotoksičnost stupnja 3 ili 4.
English: Each vial contains approximately 54 mg sodium.
Croatian: Jedna bočica sadrži približno 54 mg natrija.
English: - if you are breast-feeding; you must discontinue breast-feeding during treatment with
Croatian: - ako dojite; tijekom liječenja lijekom Pemetrexed Accord morate prestati dojiti.
English: Clinically relevant toxicity that was reported in < 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy.
Croatian: Klinički značajne toksičnosti prijavljene u < 1% bolesnika randomiziranih da primaju cisplatin i pemetreksed uključuju: povišene vrijednosti GGT-a, bol u prsima, aritmiju i motoričku neuropatiju.
English: Pemetrexed Accord is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).
Croatian: Pemetrexed Accord je indicirana kao monoterapija u drugoj liniji liječenja bolesnika s lokalno uznapredovalim ili metastatskim rakom pluća nemalih stanica kod kojeg histološki ne prevladavaju skvamozne stanice (vidjeti dio 5.1).
English: The study met its primary endpoint and showed a statistically significant improvement in PFS in the pemetrexed arm over the placebo arm (n= 581, independently reviewed population; median of 4.0 months and 2.0 months, respectively) (hazard ratio= 0.60, 95% CI= 0.49-0.73, p < 0.00001).
Croatian: Ispitivanje je ispunilo primarni ishod i pokazalo statistički značajno poboljšanje PFS-a u skupini koja je primala pemetreksed u odnosu na skupinu koja je primala placebo (N=581, neovisno procijenjena populacija; medijan od 4 odnosno 2 mjeseca) (omjer hazarda = 0,60, 95% CI = 0,49-0,73, p < 0,00001).
English: The independent review of patient scans confirmed the findings of the investigator assessment of PFS. For randomised patients, as measured from the start of pemetrexed plus cisplatin first line induction treatment, the median investigator-assessed PFS was 6.9 months for the pemetrexed arm and 5.6 months for the placebo arm (hazard ratio = 0.59 95 % CI = 0.47-0.74).
Croatian: Prema procjeni ispitivača medijan PFS-a randomiziranih bolesnika, mjeren od početka prve linije uvodnog liječenja pemetreksedom i cisplatinom, iznosio je 6,9 mjeseci za skupinu koja je primala pemetreksed i 5,6 mjeseci za skupinu s placebom (omjer hazarda = 0,59 95% CI = 0,47-0,74).
English: The resulting solution is clear and ranges in colour from colourless to yellow or green-yellow without adversely affecting product quality.
Croatian: Dobivena otopina je bistra i u rasponu boja od bezbojne do žute ili zeleno-žute što ne utječe nepovoljno na kvalitetu lijeka. pH pripremljene otopine je između 6,6 i 7,8.